Cell MedX Corp.: management transactions · United States · SEC (Form 4)

About Cell MedX Corp.

Cell MedX Corp. (ticker: CMXC) is a U.S.-based healthcare/biotech company that, according to its SEC filings, was incorporated in Nevada on March 19, 2010. For international investors, the key point is that it is an American issuer operating from the United States and presenting itself within the U.S. public-markets framework; your requested market label is NYSE/NASDAQ, although the company’s recent filings indicate OTC trading rather than a major exchange listing. The company also operates through a Canadian subsidiary, Cell MedX (Canada) Corp., formed in April 2016. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1493712/000139390523000350/cmxc-20230831.htm)) From a business-model perspective, Cell MedX describes itself as a biotech focused on the discovery, development, and commercialization of therapeutic and non-therapeutic products intended to support general wellness, pain relief, and the alleviation of complications associated with medical conditions including diabetes, Parkinson’s disease, high blood pressure, neuropathy, and kidney function. Its core proprietary platform is eBalance®, a technology it says harnesses microcurrents and their effects on the human body. The Canadian subsidiary is presented as the entity involved in the development and manufacturing of therapeutic devices built around that platform. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1493712/000139390523000350/cmxc-20230831.htm)) In competitive terms, this is a very early-stage microcap healthcare story rather than a mature commercial platform. The SEC record suggests limited revenues historically, ongoing reliance on financing from insiders and related parties, and repeated capital-structure complexity. That places CMXC in a highly speculative segment where execution risk, liquidity risk, and dilution risk matter as much as the underlying technology narrative. Investors should therefore assess it less like a mainstream listed medtech name and more like a development-stage biotech/device company still trying to prove its commercial and regulatory case. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1493712/000139390524000308/cmxc-20240531.htm)) Recent developments have been heavily shaped by compliance and financing issues. The company disclosed a cease trade order issued by the British Columbia Securities Commission in October 2022 for late filings, followed by later efforts to restore compliance by filing the missing Canadian disclosures in 2023 and requesting that the order be lifted. More recent filings also show debt settlements, conversions of debt into common shares, and recurring obligations to management, directors, and other related parties. Those items are important for equity investors because they can affect governance perception, capital availability, and future share dilution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1493712/000139390523000350/cmxc-20230831.htm)) Overall, Cell MedX Corp. is a small U.S. healthcare issuer with a Canada-linked operating footprint, built around its eBalance® microcurrent concept. The investment case depends on whether the company can convert a wellness-oriented technology narrative into sustained commercial traction while navigating regulatory compliance, financing constraints, and a potentially dilutive capital structure. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1493712/000139390523000350/cmxc-20230831.htm))